(±) -Lisofylline-d4

(±) -Lisofylline-d4 ((±) -Lisophylline-d4) is deuterium labeled (±) -Lisofylline. (±) -Lisofylline ((±) -Lisophylline) is the racemate of Lisofylline. Lisofylline inhibits the generation of phosphatidic acid and free fatty acids. Lisofylline also blocks the release of pro-inflammatory cytokines in oxidative tissue injury, in response to cancer chemotherapy and in experimental sepsis. Lisofylline can be used for Type 1 diabetes research[1].

Product Specifications

CAS Number

[1185879-05-3]

Product Name Alternative

(±) -Lisophylline-d4

UNSPSC

12352005

Target

Interleukin Related; Isotope-Labeled Compounds

Related Pathways

Immunology/Inflammation; Others

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Metabolic Disease; Inflammation/Immunology

Smiles

O=C1C2=C(N=CN2C([2H])([2H])[2H])N(C(N1CCCCC(O)([2H])C)=O)C

Molecular Formula

C13H16D4N4O3

Molecular Weight

284.35

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Yang Z, et al. Lisofylline: a potential lead for the treatment of diabetes. Biochem Pharmacol. 2005 Jan 1;69 (1) :1-5.